Douglas J.  Seith net worth and biography

Douglas Seith Biography and Net Worth

COO of AtriCure
Douglas J. Seith has served as our Chief Operating Officer since January 2015, having previously served as our Senior Vice President, Sales and Marketing from 2013 to 2014 and as our Vice President, United States Sales from 2011 to 2013. Since joining AtriCure in 2004 as a Regional Sales Leader, Mr. Seith has held a variety of progressive sales and sales leadership positions, including Area Director roles. Mr. Seith has over 30 years of cardiothoracic, cardiology and general surgery sales and sales and marketing leadership experience. Prior to joining AtriCure, Mr. Seith held sales leadership and/or sales positions with A-Med/EmoblX, Inc., where he was the Vice President of Sales, Heartport, Inc., Scimed Life Systems, a division of Boston Scientific, Inc. and Automated Instruments (a division of United States Surgical Corporation). Mr. Seith received his B.A. from Ohio Wesleyan University.

What is Douglas J. Seith's net worth?

The estimated net worth of Douglas J. Seith is at least $2.03 million as of February 2nd, 2021. Mr. Seith owns 95,939 shares of AtriCure stock worth more than $2,033,907 as of June 20th. This net worth estimate does not reflect any other assets that Mr. Seith may own. Additionally, Mr. Seith receives a salary of $1,200,000.00 as COO at AtriCure. Learn More about Douglas J. Seith's net worth.

How old is Douglas J. Seith?

Mr. Seith is currently 58 years old. There are 6 older executives and no younger executives at AtriCure. Learn More on Douglas J. Seith's age.

What is Douglas J. Seith's salary?

As the COO of AtriCure, Inc., Mr. Seith earns $1,200,000.00 per year. The highest earning executive at AtriCure is Mr. Michael H. Carrel, CEO, President & Director, who commands a salary of $2,010,000.00 per year. Learn More on Douglas J. Seith's salary.

How do I contact Douglas J. Seith?

The corporate mailing address for Mr. Seith and other AtriCure executives is 7555 INNOVATION WAY, MASON OH, 45040. AtriCure can also be reached via phone at (513) 755-4100 and via email at [email protected]. Learn More on Douglas J. Seith's contact information.

Has Douglas J. Seith been buying or selling shares of AtriCure?

Douglas J. Seith has not been actively trading shares of AtriCure in the last ninety days. Most recently, Douglas J. Seith sold 21,444 shares of the business's stock in a transaction on Monday, September 13th. The shares were sold at an average price of $75.54, for a transaction totalling $1,619,879.76. Learn More on Douglas J. Seith's trading history.

Who are AtriCure's active insiders?

AtriCure's insider roster includes Tonya Austin (Insider), Mark Collar (Director), Vinayak Doraiswamy (Insider), Scott Drake (Director), Regina Groves (Director), David Grumhaus, Jr. (Portfolio Manager), Justin Noznesky (Insider), Salvatore Privitera (Insider), Douglas Seith (COO), Sven Wehrwein (Director), and Angela Wirick (CFO). Learn More on AtriCure's active insiders.

Are insiders buying or selling shares of AtriCure?

During the last year, AtriCure insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $111,250.00. During the last year, insiders at the medical device company sold shares 7 times. They sold a total of 19,281 shares worth more than $742,976.93. The most recent insider tranaction occured on May, 30th when insider Salvatore Privitera bought 5,000 shares worth more than $111,250.00. Insiders at AtriCure own 3.2% of the company. Learn More about insider trades at AtriCure.

Information on this page was last updated on 5/30/2024.

Douglas J. Seith Insider Trading History at AtriCure

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/13/2021Sell21,444$75.54$1,619,879.76View SEC Filing Icon  
8/9/2021Sell7,065$80.79$570,781.35View SEC Filing Icon  
2/2/2021Sell14,941$60.00$896,460.0095,939View SEC Filing Icon  
12/17/2020Sell18,617$50.00$930,850.00110,880View SEC Filing Icon  
10/9/2020Sell29,161$40.09$1,169,064.49129,497View SEC Filing Icon  
1/16/2020Sell25,471$36.00$916,956.00106,272View SEC Filing Icon  
1/14/2020Sell36,363$34.00$1,236,342.00131,743View SEC Filing Icon  
9/16/2019Sell48,804$25.63$1,250,846.52208,281View SEC Filing Icon  
12/3/2015Sell5,000$21.55$107,750.00125,215View SEC Filing Icon  
3/5/2015Sell36,688$17.51$642,406.88View SEC Filing Icon  
See Full Table

Douglas J. Seith Buying and Selling Activity at AtriCure

This chart shows Douglas J Seith's buying and selling at AtriCure by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AtriCure Company Overview

AtriCure logo
AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Read More

Today's Range

Now: $21.20
Low: $18.94
High: $23.26

50 Day Range

MA: $22.48
Low: $19.86
High: $25.31

2 Week Range

Now: $21.20
Low: $18.94
High: $59.61

Volume

3,498,011 shs

Average Volume

538,934 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42